Metabolic and Pharmacokinetic Differentiation of STX209 and Racemic Baclofen in Humans

@inproceedings{SanchezPonce2012MetabolicAP,
  title={Metabolic and Pharmacokinetic Differentiation of STX209 and Racemic Baclofen in Humans
},
  author={Raymundo Sanchez-Ponce and Li-Quan Wang and Wei Lu and Jana von Hehn and Maryann Cherubini and Roger Rush},
  booktitle={Metabolites},
  year={2012}
}
STX209 is an exploratory drug comprising the single, active R-enantiomer of baclofen which is in later stage clinical trials for the treatment of fragile x syndrome (FXS) and autism spectrum disorders (ASD). New clinical data in this article on the metabolism and pharmacokinetics of the R- and S-enantiomers of baclofen presents scientific evidence for stereoselective metabolism of only S-baclofen to an abundant oxidative deamination metabolite that is sterically resolved as the S-enantiomeric… CONTINUE READING
Recent Discussions
This paper has been referenced on Twitter 1 time over the past 90 days. VIEW TWEETS

References

Publications referenced by this paper.
Showing 1-10 of 29 references

Single-Dose Plasma pk parameters of arbaclofen, r-baclofen and s-baclofen

  • G. Meyer, G. Fishbein, D. Boyd
  • In Proceedings of 40th Annual Meeting of the…
  • 2011
2 Excerpts

Similar Papers

Loading similar papers…